Hsbc Holdings PLC Buys 3,534 Shares of Novo Nordisk A/S (NYSE:NVO)

Hsbc Holdings PLC raised its stake in Novo Nordisk A/S (NYSE:NVOFree Report) by 5.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,520 shares of the company’s stock after acquiring an additional 3,534 shares during the quarter. Hsbc Holdings PLC’s holdings in Novo Nordisk A/S were worth $6,881,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. CNB Bank acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $26,000. Pacific Center for Financial Services grew its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Valued Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $28,000. Bell Investment Advisors Inc grew its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Finally, Tyler Stone Wealth Management grew its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on NVO. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $137.33.

Check Out Our Latest Report on Novo Nordisk A/S

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $135.62 on Tuesday. The company has a market cap of $608.60 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The firm has a 50 day simple moving average of $128.69 and a 200 day simple moving average of $118.13. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. Research analysts predict that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Recommended Stories

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.